394 related articles for article (PubMed ID: 28444639)
1. Metformin and Prostate Cancer: a New Role for an Old Drug.
Whitburn J; Edwards CM; Sooriakumaran P
Curr Urol Rep; 2017 Jun; 18(6):46. PubMed ID: 28444639
[TBL] [Abstract][Full Text] [Related]
2. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
Hankinson SJ; Fam M; Patel NN
Urol Oncol; 2017 Jan; 35(1):21-29. PubMed ID: 27836248
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
4. Metformin in prostate cancer: two for the price of one.
Clements A; Gao B; Yeap SHO; Wong MKY; Ali SS; Gurney H
Ann Oncol; 2011 Dec; 22(12):2556-2560. PubMed ID: 21421541
[TBL] [Abstract][Full Text] [Related]
5. Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review.
Ahn HK; Lee YH; Koo KC
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198356
[TBL] [Abstract][Full Text] [Related]
6. Metabolic roles of AMPK and metformin in cancer cells.
Choi YK; Park KG
Mol Cells; 2013 Oct; 36(4):279-87. PubMed ID: 23794020
[TBL] [Abstract][Full Text] [Related]
7. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.
Martin-Castillo B; Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
Cell Cycle; 2010 Mar; 9(6):1057-64. PubMed ID: 20305377
[TBL] [Abstract][Full Text] [Related]
8. The anticancer potential of metformin on prostate cancer.
Zaidi S; Gandhi J; Joshi G; Smith NL; Khan SA
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):351-361. PubMed ID: 30651580
[TBL] [Abstract][Full Text] [Related]
9. Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes.
Aboelnaga EM; Aboelnaga MM; Elkalla HM
Diabetes Metab Syndr; 2021; 15(5):102251. PubMed ID: 34428740
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
Zhu W; Xu H; Ma J; Guo J; Xue W; Gu B; Sheng L; Yao X; Sun F; Gong J; Qiu W; Ding Q; Jiang H
Urol Int; 2017; 98(1):79-84. PubMed ID: 27684440
[TBL] [Abstract][Full Text] [Related]
11. Metformin in cancer: translational challenges.
Dowling RJ; Niraula S; Stambolic V; Goodwin PJ
J Mol Endocrinol; 2012 Jun; 48(3):R31-43. PubMed ID: 22355097
[TBL] [Abstract][Full Text] [Related]
12. Metformin and prostate cancer stem cells: a novel therapeutic target.
Mayer MJ; Klotz LH; Venkateswaran V
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):303-9. PubMed ID: 26215782
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
14. [Docetaxel for metastatic prostate cancer: early is better].
Gietema JA; Oosting SF
Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
16. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients.
Kiwata JL; Dorff TB; Schroeder ET; Gross ME; Dieli-Conwright CM
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):323-332. PubMed ID: 27349496
[TBL] [Abstract][Full Text] [Related]
17. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
18. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Guppy A; Jamal-Hanjani M; Pickering L
Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
[TBL] [Abstract][Full Text] [Related]
19. Repurposing metformin for the prevention of cancer and cancer recurrence.
Heckman-Stoddard BM; DeCensi A; Sahasrabuddhe VV; Ford LG
Diabetologia; 2017 Sep; 60(9):1639-1647. PubMed ID: 28776080
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]